File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Phacoemulsification Cataract Surgery in Patients Receiving Novel Oral Anticoagulant

TitlePhacoemulsification Cataract Surgery in Patients Receiving Novel Oral Anticoagulant
Authors
Issue Date2018
PublisherAssociation for Research in Vision and Ophthalmology. The Journal's web site is located at http://www.iovs.org
Citation
The Association of Research in Vision and Ophthalmology Annual Meeting, Honolulu, HI, 29 April-3 May 2018. In Investigative Ophthalmology & Visual Science, 2018, v. 59 n. 9, p. 2222 How to Cite?
AbstractPurpose : To assess the risk of intraoperative and postoperative bleeding in patients receiving novel oral anticoagulation (NOAC) while undergoing phacoemulsification surgery. Methods : A retrospective study reviewed the electronic records of consecutive patients receiving NOAC during the time of phacoemulsification surgery over a 4-year period (from January 2012 through to September 2016). Patients were either advised to stop medication before surgery (withheld group) or continue medication throughout the surgery (continued group). Details including patient demographics, preoperative assessment, surgical details, postoperative outcome and intraoperative, postoperative and systemic complications were all recorded. Results : A total of 66 eyes of 53 patients were included, 42 continued and 24 withheld medication before surgery. There was no statistically significant difference between the two groups in demographics, cataract risk factors, baseline renal function and clotting profile, type of NOAC, wound size, phacoemulsification energy and pre-operative or post-operative visual acuity. There was also no significant difference in post-operative and systemic complications (p= 1.00 and 0.53, Fischer’s exact test). None of the patients in the continued group had post-operative complications; two cases in the withheld group had bruising and subconjunctival hemorrhage, which were self-limiting in nature (p=0.13, Fischer’s exact test). The only significant difference between the two groups was the mode of anesthesia (p = 0.01, Fischer’s exact test). Conclusions : Continuation of NOAC medications during phacoemulsification surgery appears safe, with low risk of intraoperative and postoperative haemorrhagic complications. The choice to continue or withhold NOAC perioperatively should be balanced with potential benefit and risk with a multidisciplinary approach.
Persistent Identifierhttp://hdl.handle.net/10722/258477
ISSN
2015 Impact Factor: 3.427
2015 SCImago Journal Rankings: 2.008

 

DC FieldValueLanguage
dc.contributor.authorCheung, JJC-
dc.contributor.authorLi, KKW-
dc.contributor.authorLiu, S-
dc.date.accessioned2018-08-22T01:39:04Z-
dc.date.available2018-08-22T01:39:04Z-
dc.date.issued2018-
dc.identifier.citationThe Association of Research in Vision and Ophthalmology Annual Meeting, Honolulu, HI, 29 April-3 May 2018. In Investigative Ophthalmology & Visual Science, 2018, v. 59 n. 9, p. 2222-
dc.identifier.issn0146-0404-
dc.identifier.urihttp://hdl.handle.net/10722/258477-
dc.description.abstractPurpose : To assess the risk of intraoperative and postoperative bleeding in patients receiving novel oral anticoagulation (NOAC) while undergoing phacoemulsification surgery. Methods : A retrospective study reviewed the electronic records of consecutive patients receiving NOAC during the time of phacoemulsification surgery over a 4-year period (from January 2012 through to September 2016). Patients were either advised to stop medication before surgery (withheld group) or continue medication throughout the surgery (continued group). Details including patient demographics, preoperative assessment, surgical details, postoperative outcome and intraoperative, postoperative and systemic complications were all recorded. Results : A total of 66 eyes of 53 patients were included, 42 continued and 24 withheld medication before surgery. There was no statistically significant difference between the two groups in demographics, cataract risk factors, baseline renal function and clotting profile, type of NOAC, wound size, phacoemulsification energy and pre-operative or post-operative visual acuity. There was also no significant difference in post-operative and systemic complications (p= 1.00 and 0.53, Fischer’s exact test). None of the patients in the continued group had post-operative complications; two cases in the withheld group had bruising and subconjunctival hemorrhage, which were self-limiting in nature (p=0.13, Fischer’s exact test). The only significant difference between the two groups was the mode of anesthesia (p = 0.01, Fischer’s exact test). Conclusions : Continuation of NOAC medications during phacoemulsification surgery appears safe, with low risk of intraoperative and postoperative haemorrhagic complications. The choice to continue or withhold NOAC perioperatively should be balanced with potential benefit and risk with a multidisciplinary approach.-
dc.languageeng-
dc.publisherAssociation for Research in Vision and Ophthalmology. The Journal's web site is located at http://www.iovs.org-
dc.relation.ispartofInvestigative Ophthalmology & Visual Science-
dc.titlePhacoemulsification Cataract Surgery in Patients Receiving Novel Oral Anticoagulant-
dc.typeConference_Paper-
dc.identifier.emailCheung, JJC: janicejc@hku.hk-
dc.identifier.authorityCheung, JJC=rp02219-
dc.identifier.hkuros287706-
dc.identifier.volume59-
dc.identifier.issue9-
dc.identifier.spage2222-
dc.identifier.epage2222-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats